Doxorubicin–polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics

Chun, ChangJu; Lee, Sun M.; Kim, Chang W.; Hong, Ki Yun; Kim, Sang Yong; Yang, Han–Kwang; Song, Soo‐Chang

doi:10.1016/j.biomaterials.2009.05.031

Cited by 117 publications

(60 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over more than 20 days, the release rate of doxorubicin was successfully controlled by altering the mechanical strength of polyphosphazene. Later, Song and colleagues exploited a conjugation strategy involving doxorubicin and paclitaxel as therapeutic agents coupled to a polyphophazene backbone for local tumor treatment [94,95]. Another method of conjugation in polyphosphazene hydrogels involves a modification with protamine or poly-L-arginine for the delivery of human growth hormone (hGH) [96], which results in poly-L-arginine-or protamine-modified poplyphosphazene releasing hGH for up to 5 days in vivo or 7 days in vitro, respectively.…”

Section: Temperature Sensitive Hydrogelsmentioning

confidence: 98%

Injectable polymeric hydrogels for the delivery of therapeutic agents: A review

Nguyễn

Huynh

Park

et al. 2015

European Polymer Journal

203

120

View full text Add to dashboard Cite

Section: Temperature Sensitive Hydrogelsmentioning

confidence: 98%

Injectable polymeric hydrogels for the delivery of therapeutic agents: A review

Nguyễn

Huynh

Park

et al. 2015

European Polymer Journal

203

120

View full text Add to dashboard Cite

“…It was observed that the toxicity of DOX was reduced in conjugated form. [33] Kholar et al [34] immobilized the methotrexate on dextran-coated iron oxide nanoparticles and provided evidence that the drug loading on such nanoparticles was possible due to electrostatic interaction between the positively charged methotrexate and negatively charged polymer layer on nanoparticles. It was observed that the change in pH is sufficient to release the medicine from nanoparticles.…”

Section: Discussionmentioning

confidence: 97%

Anticancer Medicines (Doxorubicin and Methotrexate) Conjugated With Magnetic Nanoparticles for Targeting Drug Delivery Through Iron

Samra

Ahmad

Javeid

et al. 2013

Preparative Biochemistry and Biotechnology

View full text Add to dashboard Cite

The uptake of iron is increased by cancer cells. Iron magnetic nanoparticles (MNP) can be used as a nanovehicle for immobilization of anticancer medicines and to integrate them at a target site. The anticancer medicines doxorubicin (DOX) and methotrexate (MTX) were immobilized separately and in combination onto MNP by a glutaraldehyde activation method and confirmed by magnetic nanoparticles linked immunosorbent assay (MagLISA) and Fourier-transform infrared (FTIR) spectroscopy. The phenol peaks of DOX and MTX at 2896.6 cm⁻¹ to 2912.5 cm⁻¹ in FTIR spectra of immobilized medicines indicated the conjugation. Affinity-purified anti-DOX and anti-MTX antibodies were used to evaluate the coupling of DOX and MTX onto MNP, and the binding was found 34.6% to 37.2% and 51.8% to 54.3% separately, respectively. The immobilization of DOX and MTX in combination onto MNP was 18% and 27%, respectively. HeLa and B cells were cultured with DOX-MNP, MTX-MNP, and DOX-MNP-MTX separately, and MagLISA indicated that the binding of DOX-MNP/MTX-MNP was 41.5% to 45% with HeLa cells and 20% to 26% with B cells. No significant difference was observed in binding of DOX-MNP-MTX with HeLa and B cells. Results also indicated that the release of medicines at pH 5.0 is more (39% to 44%) than at pH 7.4 (3.7% to 10.2%). Sixteen to 22% more killing effect was observed on HeLa cells than on B cells. In immunohistochemical staining, more deposition of brown color on HeLa cells than on B cells may be due to more expression of iron-binding sites on cancer cells. The dual property of MNP can be used for binding of medicines and for targeting drug delivery.

show abstract

“…Consequently, thermal and mechanical properties of PPZ greatly vary with T g ranging from −10 to 35 °C, contact angle 63°-107°, tensile strength 2.4-7.6 MPa, and modulus of elasticity 31.4-455.9 MPa [264]. PPZ are fabricated into particles, micelles, microneedle coatings, and gels for the delivery of anti-inflammatory drugs, chemotherapeutics, growth factors, DNA, proteins, and vaccines [265][266][267][268]. Moreover, PPZ scaffolds composed of films, fibers, and microspheres are used to assist nerve regeneration and orthopedic applications, alone or blended with polyesters to increase mechanical strength and provide a moderate pH microenvironment for developing tissues [269][270][271].…”

Section: Polyphosphazenesmentioning

confidence: 99%